HIG1 hypoxia inducible domain family member 1A pseudogene 8Genealiases: []
Q-omics provides the consensus-scored HIGD1AP8 profile across patient tissues and cancer cell-line models. HIGD1AP8 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HIGD1AP8 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, HIGD1AP8 RNA expression shows 5,452 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, STAD, and HNSC as cancer lineages where HIGD1AP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1AP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1AP8 survival associations across molecular data types. HIGD1AP8 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1AP8 RNA expression–survival associations across cancer types. High HIGD1AP8 expression shows unfavorable associations in MESO, KICH, ACC and UVM, but favorable associations in SKCM and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HIGD1AP8 RNA expression.
This table summarizes HIGD1AP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for HIGD1AP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1AP8 shows lower tumor expression in KIRP and higher tumor expression in STAD, BRCA, LUSC, KICH and PRAD. The STAD box plot shows higher HIGD1AP8 RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p = .011).
This table shows molecular features associated with HIGD1AP8 in patient tissues and cancer cell lines. In patient samples, HIGD1AP8 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
